Today MedMen will go public via RTO in Canada on the CSE in what appears to be the most perplexing offering we have ever seen. MedMen, captained by CEO Adam Bierman is a chain of luxury Dispensaries in various states with an Apple store kind of feel. These 12 dispensary locations are predominantly leased which isn’t shocking. What is shocking is the valuation this is coming out at! Are you ready?!
$1,650,000,000 Valuation, those extra three zeroes were not a typo. Yes if you do some math the value of each dispensary is about $137,500,000 per location that is not owned, is rented and mainly in a state where dispensaries are on every other block. On the saturation modeling alone MedMen $Mmen.c is a hyper inflated company. We understand the razzle dazzle of the markets and new offerings as well as realize they aren’t the only hyper inflated company out there.
We also think (and we say this with honesty) Adam Bierman is probably the best salesman we have seen in a long while in the Cannabis space. As one huge fund manager said to us yesterday “The guy could sell ice to Inuits!” Why is he a great salesman you might ask? If you look at the compensation structure and the level of control he and the CFO have it’s unreal! We promise that you will believe the numbers to be typos and not real. We know that because when we were getting intel on this and talking to some big banks out there they asked if these numbers were jokes. For more detail on the compensation & voting we implore you to read this piece by Chris Parry at Equity.guru.
Full disclosure: No one affiliated or working for, writing for, delivering coffee to marijuanastocks.com or Wolf of weed street have any positions long or short in MedMen nor have any intention on getting a position.

 


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Marijuana Stocks Newsletter – Top Trending Stories on Wednesday July 25, 2018

GT Biopharma Inc. (GTBP) Announces the Addition of Dr. John N. Bonfiglio…